JP2023514659A5 - - Google Patents
Info
- Publication number
- JP2023514659A5 JP2023514659A5 JP2022537837A JP2022537837A JP2023514659A5 JP 2023514659 A5 JP2023514659 A5 JP 2023514659A5 JP 2022537837 A JP2022537837 A JP 2022537837A JP 2022537837 A JP2022537837 A JP 2022537837A JP 2023514659 A5 JP2023514659 A5 JP 2023514659A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- seq
- interferon
- homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AR20190103715 | 2019-12-17 | ||
| ARP190103715A AR117715A1 (es) | 2019-12-17 | 2019-12-17 | Interferón hiperglicosilado con inmunogenicidad reducida |
| PCT/US2020/065246 WO2021126929A1 (en) | 2019-12-17 | 2020-12-16 | Modified interferon-alpha-2 having reduced immunogenicity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023514659A JP2023514659A (ja) | 2023-04-07 |
| JP2023514659A5 true JP2023514659A5 (cg-RX-API-DMAC7.html) | 2023-12-25 |
| JP7786010B2 JP7786010B2 (ja) | 2025-12-16 |
Family
ID=76478524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537837A Active JP7786010B2 (ja) | 2019-12-17 | 2020-12-16 | 免疫原性が低下した修飾インターフェロン-アルファ-2 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230127506A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4076504A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7786010B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR117715A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022011975A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007546A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021126929A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| KR20250048583A (ko) | 2022-08-18 | 2025-04-09 | 리제너론 파아마슈티컬스, 인크. | 인터페론 전구단백질 및 이의 용도 |
| KR20260026098A (ko) | 2023-05-12 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 인터페론 수용체 길항제 및 이의 용도 |
| CN116814595B (zh) * | 2023-08-30 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种腺苷脱氨酶突变体及其固定化 |
| WO2026104336A1 (en) | 2024-11-13 | 2026-05-21 | F. Hoffmann-La Roche Ag | Immunoconjugates |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| EP1379555A2 (en) * | 2001-03-02 | 2004-01-14 | MERCK PATENT GmbH | Modified interferon alpha with reduced immunogenicity |
| MX2007001589A (es) * | 2004-08-09 | 2007-08-02 | Alios Biopharma Inc | Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas. |
| KR20080026135A (ko) | 2005-06-03 | 2008-03-24 | 암브룩스, 인코포레이티드 | 개선된 인간 인터페론 분자 및 이의 용도 |
| JP5208733B2 (ja) | 2005-06-29 | 2013-06-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 組換えインターフェロンα2(IFNα2)変異体 |
| AR057215A1 (es) | 2006-12-01 | 2007-11-21 | Univ Nac Del Litoral Unl | Proteina de fusion |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| CA2695543A1 (en) | 2007-08-06 | 2009-02-12 | Schering Corporation | Gamma secretase modulators |
| PE20170908A1 (es) | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
| AR102120A1 (es) * | 2015-09-29 | 2017-02-08 | Univ Nac Del Litoral | Interferón modificado con inmunogenicidad reducida |
| JP7534215B2 (ja) | 2018-01-24 | 2024-08-14 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | サイトカイン融合タンパク質 |
-
2019
- 2019-12-17 AR ARP190103715A patent/AR117715A1/es unknown
-
2020
- 2020-12-16 WO PCT/US2020/065246 patent/WO2021126929A1/en not_active Ceased
- 2020-12-16 EP EP20901063.6A patent/EP4076504A4/en active Pending
- 2020-12-16 BR BR112022011975A patent/BR112022011975A2/pt not_active IP Right Cessation
- 2020-12-16 JP JP2022537837A patent/JP7786010B2/ja active Active
- 2020-12-16 US US17/783,948 patent/US20230127506A1/en active Pending
- 2020-12-16 MX MX2022007546A patent/MX2022007546A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| JP2022115876A5 (cg-RX-API-DMAC7.html) | ||
| TWI648401B (zh) | 生長分化因子15(gdf-15)構築體 | |
| JP2004536077A5 (cg-RX-API-DMAC7.html) | ||
| JP7702445B2 (ja) | 免疫調節融合タンパク質 | |
| JP2021512126A5 (cg-RX-API-DMAC7.html) | ||
| CA2529179A1 (en) | Recombinant adeno-associated virus vector for treatment of alzheimer disease | |
| JP2016519569A5 (cg-RX-API-DMAC7.html) | ||
| RU2012107671A (ru) | Композиция для лечения инфекции вирусом гепатита в | |
| CA2308116A1 (en) | Low-toxicity human interferon-alpha analog | |
| CN111954537A (zh) | 生长分化因子15融合蛋白 | |
| JP2007535910A5 (cg-RX-API-DMAC7.html) | ||
| BG64920B1 (bg) | Комплекс ifnar2/ifn | |
| CN111499718A (zh) | 人α干扰素受体结合相关位点突变体及其用途 | |
| WO2004101617A1 (en) | Active variants of the il-18 binding protein and medical uses thereof | |
| JP2024525213A5 (cg-RX-API-DMAC7.html) | ||
| RU2010141916A (ru) | Растворимый мутант рецептора фактора некроза опухоли | |
| JP5209462B2 (ja) | コンセンサスインターフェロンの使用方法 | |
| US7642072B2 (en) | Optimized interferon-beta gene | |
| JP2023522423A (ja) | インターフェロンアルファ2バリアント及びその使用 | |
| JP2025516139A5 (cg-RX-API-DMAC7.html) | ||
| JP2020518270A (ja) | タンパク質の半減期を増加させる方法 | |
| WO2003059950A1 (en) | Ifnar2 mutants, their production and use | |
| Garotta et al. | Development of interferon-γ antagonists as an example of biotechnology application to approach new immunomodulators | |
| WO2021233094A1 (zh) | 干扰素-κ突变体及其制备方法 |